Table 2.
| Case number | Intratumoral TILs | Intratumoral CD4+/CD8+ ratio | Peritumoral-infiltrating lymphocytes | Peritumoral CD4+/CD8+ ratio | Baseline circulating CD4+/CD8+ ratio | Circulating CD4+/CD8+ ratio after therapy | Treatment response according to irRECIST |
| Case N. 6954 | Low | 1:2 | Low | 1:3 | 2.5 | 3 | PD (progression of disease) |
| Case N. 8205 | High | 1:3 | High | 3:1 | 3.5 | 4.9 | PR (Partial response) |
| Case N. 10622 | Low | 2:1 | High | 1:2 | 1 | 0.9 | SD (stable disease) |
| Case N. 15859 | Moderate | 1:2 | Moderate | 1:2 | 0.9 | NE (not evaluated) | PD |
| Case N. 18659 | Low | 1:2 | High | 1:2 | 1.1 | 1.1 | PD |
| Case N. 7985 | Low | only CD8+ | Moderate | 1:2 | 2.7 | 2.2 | SD |
| Case N. 2011 | High | 1:3 | Moderate | 1:2 | NE | NE | PD |
| Case N. 274 | Moderate | 1:3 | Moderate | 1:2 | 2.8 | 2.4 | PD |
| Case N. 5007 | High | 1:2 | High | 1:2 | 0.5 | 0.4 | PD |
| Case N. 552 | High | 1:2 | High | 1:3 | 2.5 | 3.8 | SD |
| Case N. 25620 | Low | 2:1 | Low | 1:2 | 0.3 | 0.4 | SD |